Data completeness
3/8 — Basic
CARDRASE (ethoxzolamide) by Pfizer is clinical pharmacology methazolamide is a potent inhibitor of carbonic anhydrase. Approved for the treatment of ocular conditions where lowering intraocular pressure is likely to be of therapeutic benefit, such, secondary glaucoma and 1 more indications.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CARDRASE (ethoxzolamide) is an oral tablet small molecule in pre-launch development by Pfizer with an approved NDA. The specific therapeutic indications, mechanism of action, and clinical profile are not yet publicly detailed in available data.
Pre-Launch
Pre-launch stage indicates active team building for launch preparation; immediate career opportunities exist in commercial planning, regulatory affairs, and medical affairs functions.
Mechanism of Action
CLINICAL PHARMACOLOGY Methazolamide is a potent inhibitor of carbonic anhydrase. Methazolamide is well absorbed from the gastrointestinal tract. Peak plasma concentrations are observed 1 to 2 hours after dosing. In a multiple-dose, pharmacokinetic study, administration of methazolamide 25 mg bid,…
Worked on CARDRASE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.